Bpifrance eyes investment in Sanofi's consumer health business
July 4 (Reuters) -Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's SASY.PA consumer health unit, Bloomberg News reported on Thursday.
The French public investment bank is in talks with "many funds" and may team up with the winning bidder for Sanofi's consumer health unit, Gonzalo was quoted as saying.
Bpifrance confirmed Gonzalo had made the comments on Sanofi's consumer health unit and other potential investments during a briefing on Thursday.
Sanofi said in an emailed statement that it does not comment on market rumours, adding that the French drugmaker was progressing with its preparations for a potential separation of the consumer health business, while keeping all options open.
Gonzalo said Bpifrance is also studying an investment in tourism and travel company Club Med, the report said, in comments that were also confirmed to Reuters by BpiFrance.
Club Med did not immediately respond to requests for comment.
Private equity firm CVC Capital Partners had been in talks with Bpifrance to jointly buy a minority stake in Club Med from China's Fosun, French newspaper La Lettre reported in June.
The Bloomberg report also said that the sale of Les Laboratoires Servier's generic drugmaker Biogaran is on hold due to France's parliamentary elections, even though Bpifrance had put in a non-binding bid with BC Partners.
Biogaran did not immediately respond to a request for comment.
French Prime Minister Gabriel Attal said in May that the French government told drugmaker Servier it opposes a sale of Biogaran, which has a French market share of almost a third.
Reporting by Chandni Shah in Bengaluru; Editing by Alexander Smith
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
